Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT00318422
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
  • rosiglitazone — DRUG
  • glimepiride — DRUG

Study Details

This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride.

Key Dates

Start date
May 31, 2006
Status verified
Jan 2017
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
1,041 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

HbA1c [ Time Frame: after 26 weeks of treatment ]

Related Studies